https://scholars.lib.ntu.edu.tw/handle/123456789/511369
DC Field | Value | Language |
---|---|---|
dc.contributor.author | PO-CHIN LIANG | en_US |
dc.contributor.author | Ch’ang H.-J. | en_US |
dc.contributor.author | CHIUN HSU | en_US |
dc.contributor.author | Chen L.-T. | en_US |
dc.contributor.author | TIFFANY TING-FANG SHIH | en_US |
dc.contributor.author | Liu T.W. | en_US |
dc.creator | Po-Chin Liang;Ch?ng H.-J.;Hsu C.;Chen L.-T.;Shih T.T.F.;Liu T.W. | - |
dc.date.accessioned | 2020-08-11T08:36:46Z | - |
dc.date.available | 2020-08-11T08:36:46Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 1936-0533 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/511369 | - |
dc.description.abstract | Background: To correlate between signal parameters using dynamic contrast-enhanced magnetic resonance imaging (DCEMRI) and outcomes of hepatocellular carcinoma (HCC) receiving radiotherapy with or without concomitant thalidomide. Methods: DCEMRI was performed in advanced HCC patients undergoing radiotherapy with or without concomitant thalidomide. Initial first-pass enhancement slopes (slope) and peak enhancement ratios (peak) were measured over an operator-defined region of interest over tumor and non-tumor liver parenchyma. The perfusion parameters were correlated with clinical outcomes. The study was registered with ClinicalTrials.gov. (identifier NCT00155272). Results: Forty-three patients were evaluable. There were 18 partial responses (PRs), 5 minimal responses (MRs), 17 stable diseases (SDs), and 3 progressive diseases (PDs). Baseline perfusion parameters as well as slope at 14?days of radiotherapy were higher in patients with PR or MR compared to SD or PD (0.81?±?0.29 vs. 0.49?±?0.34, p?<?0.01; 0.39?±?0.15 vs. 0.28?±?0.16, p?=?0.02; 0.97?±?0.38 vs. 0.46?±?0.26, p?<?0.01; respectively). Multivariate analysis revealed perfusion parameters over liver parenchyma, but not over tumor, and independently predicted progression-free and overall survival (182?±?33 vs. 105?±?26?days, p?=?0.01; 397?±?111 vs. 233?±?19?days, p?=?0.001 respectively). For 22 patients receiving concomitant thalidomide, the perfusion parameters were not significantly different from those receiving radiotherapy alone. Conclusions: Signal parameters of DCEMRI over tumor and liver parenchyma correlated with tumor response and survival, respectively, in HCC patients receiving radiotherapy. ? 2014, Asian Pacific Association for the Study of the Liver. | - |
dc.relation.ispartof | Hepatology International | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | angiogenesis inhibitor; contrast medium; gadodiamide; gadolinium pentetate; thalidomide; aged; Carcinoma, Hepatocellular; clinical trial; disease free survival; female; human; Liver Neoplasms; male; multimodality cancer therapy; nuclear magnetic resonance imaging; phase 2 clinical trial; procedures; signal processing; survival rate; treatment outcome; Aged; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Combined Modality Therapy; Contrast Media; Disease-Free Survival; Female; Gadolinium DTPA; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Signal Processing, Computer-Assisted; Survival Rate; Thalidomide; Treatment Outcome | - |
dc.title | Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1007/s12072-014-9557-1 | - |
dc.identifier.pmid | 25788178 | - |
dc.identifier.scopus | 2-s2.0-84938849309 | - |
dc.relation.pages | 258-268 | - |
dc.relation.journalvolume | 9 | - |
dc.relation.journalissue | 2 | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | none | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
crisitem.author.dept | Radiology | - |
crisitem.author.dept | Medical Imaging-NTUH | - |
crisitem.author.dept | Medical Imaging-NTUHHC | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Medical Oncology-NTUCC | - |
crisitem.author.dept | Radiology | - |
crisitem.author.dept | Medical Imaging-NTUH | - |
crisitem.author.orcid | 0000-0002-6674-2926 | - |
crisitem.author.orcid | 0000-0002-1122-0055 | - |
crisitem.author.orcid | 0000-0002-3292-9688 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | NTU Hsin-Chu Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
Appears in Collections: | 醫學院附設醫院 (臺大醫院) |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.